Lisofylline

HCID 501254CAS 100324-81-0

기본 정보

표준 SMILES
C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O
InChIKey
NSMXQKNUPPXBRG-SECBINFHSA-N
분자식
C13H20N4O3
평균 분자량
280.32 g/mol
단동위원소 질량
280.1535405

개요

(R)-lisofylline is a 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione that has (R)-configuration. A synthetic small molecule which was under development for the treatment of type 1 diabetes mellitus. It has a role as an immunomodulator and an anti-inflammatory agent. It is an enantiomer of a (S)-lisofylline.

이름 및 식별자

우선 이름
Lisofylline
IUPAC
1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione

이름 및 동의어

(R)-LisofyllineLISOFYLLINE100324-81-0ProTecLisophyllineCT-1501RlisofilinaCT 1501R1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dioneLisofylline, (r)-lisofyllinumCT1501R
이름 더 보기
(R)-Lisophylline1-[(R)-5-hydroxyhexyl]theobromineDTXSID7058709CHEBI:143527L1F2Q2X9561-((R)-5-Hydroxyhexyl)theobromine1-(5R-Hydroxyhexyl)-3,7-dimethylxanthine1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione

데이터베이스 식별자

CAS
100324-81-0
PubChem CID
501254
DTXSID
DTXSID7058709
ChEMBL
CHEMBL1411
ChEBI
CHEBI:143527
UNII
L1F2Q2X956
Nikkaji
J731.039K

물성

구조 계산 물성

XLogP
0.7
극성 표면적
78.7 Ų
수소 결합 공여자 수
1
수소 결합 수용자 수
4
회전 가능 결합 수
5
무거운 원자 수
20

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals -> Metabolite of Pentoxifylline

Pharmaceuticals -> Listed in ZINC15

화학 및 산업

약리 정보

Metabolism/MetabolitesLisofylline has known human metabolites that include lisofylline 4,5-diol and pentoxifylline.
MeSH Pharmacological Classification · 4건

Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.

Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.

Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.

Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.

관련 반응

2건

연결된 노트

불러오는 중…